HHS and VA collaborate to advance psychedelic therapy

HHS and VA sign agreement

The U.S. Department of Health and Human Services (HHS) and the Department of Veterans Affairs (VA) have entered into an agreement to promote the development of psychedelic therapies, according to Becker's Behavioral Health. This collaboration aims to explore innovative treatments for mental health conditions, including the use of ibogaine for opioid use disorder.

Focus on ibogaine research

The agreement highlights the involvement of the Advanced Research Projects Agency for Health (ARPA-H), which is inviting applications to support ibogaine research. Ibogaine, a psychoactive substance, has shown potential in treating opioid addiction, making it a significant focus of this initiative.

Why it matters

This agreement marks a significant step in the exploration of psychedelic substances as potential treatments for mental health disorders. By focusing on ibogaine, the HHS and VA aim to address the opioid crisis, which continues to be a major public health challenge in the United States.

The collaboration between these federal agencies underscores the growing interest in alternative therapies that could offer new hope for individuals struggling with addiction and other mental health issues.

Further details on the agreement and its implementation are expected as the agencies move forward with their plans.